Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

BACKGROUND: We evaluated antidrug antibody (ADA) development in patients with chronic plaque psoriasis from three clinical trials of tildrakizumab, a humanized anti‐interleukin‐23p19 monoclonal antibody (P05495, reSURFACE 1 and reSURFACE 2). OBJECTIVES: To determine the effects of immunogenicity on...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Dermatol
Hlavní autoři: Kimball, A.B., Kerbusch, T., van Aarle, F., Kulkarni, P., Li, Q., Blauvelt, A., Papp, K.A., Reich, K., Montgomery, D.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2019
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6972989/
https://ncbi.nlm.nih.gov/pubmed/30916381
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjd.17918
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky